Key Highlights

  • Armata Pharmaceuticals received FDA Breakthrough Therapy Designation for intravenous AP-SA02.
  • AP-SA02 is being developed as an adjunctive therapy for complicated Staphylococcus aureus bacteremia (MSSA or MRSA).
  • The designation builds on existing QIDP and Fast Track designations.
  • It follows positive Phase 1b/2a diSArm study results showing accelerated clinical cure and zero relapses through Day 28.

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) announced the FDA granted Breakthrough Therapy designation to intravenous AP-SA02 as an adjunctive therapy for complicated Staphylococcus aureus bacteremia, covering both MSSA and MRSA.

What Happened

The designation builds on existing QIDP and Fast Track designations, following positive Phase 1b/2a diSArm study results that demonstrated favorable safety, accelerated clinical cure, zero relapses through Day 28, and encouraging biomarker signals.

Market Reaction

The disclosed information does not include stock price or trading data for Armata Pharmaceuticals following the Breakthrough Therapy designation.

Outlook

The Breakthrough Therapy designation is intended to support more frequent FDA interaction and a potentially expedited development path for AP-SA02, representing the next relevant regulatory tailwind for the program.